Clinical Trial

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab Vedotin therapy is completed, patients will be followed every 4 months for about 2 years.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-07-27; most recent amendment 2026-04-10.
Status change: Not Yet Recruiting → Recruiting 2021-10-29
Trial Details
NCT Number NCT04491370
Lead Sponsor New York Medical College
Conditions B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Non-Hodgkin Lymphoma, Richter Syndrome +1 more
Enrollment 20 participants
Start Date 2021-08-01
Primary Completion 2026-08-15 (estimated)
Study Completion 2027-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-15